Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07566754 Metronidazole Bacterial Vaginosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07566754 clinical trial report covering Metronidazole, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261646 Shiwei Shufeng Granules Acute eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261646 clinical trial report covering Shiwei Shufeng Granules, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07568730 Lacripep Neurotrophic keratitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07568730 clinical trial report covering Lacripep, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124010 Ipilimumab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124010 clinical trial report covering Ipilimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124058 Enzalutamide Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124058 clinical trial report covering Enzalutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07571746 Surovatamig Idiopathic Membranous Glomerulonephritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07571746 clinical trial report covering Surovatamig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07569068 Tislelizumab CLDN18.2 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07569068 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07570745 Ivarmacitinib Acute Graft Versus Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07570745 clinical trial report covering Ivarmacitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261421 Soficitinib Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261421 clinical trial report covering Soficitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07570758 ERX 1000 analogues (ERX Pharmaceuticals) Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07570758 clinical trial report covering ERX 1000 analogues (ERX Pharmaceuticals), Phase 2, endpoints, sponsor, geography, readout timing and development wh
Latest Hotspot
8 min read
NCT07570914 Irinotecan Hydrochloride Lioposome Liver metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07570914 clinical trial report covering Irinotecan Hydrochloride Lioposome, Phase 2, endpoints, sponsor, geography, readout timing and development white sp
Latest Hotspot
8 min read
NCT07569198 Ketamine Hydrochloride Borderline Personality Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07569198 clinical trial report covering Ketamine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.